VYNE
Vyne Therapeutics
$28.56
+$3.11 (+12.22%)Jul 27, 2026
Key metrics
The numbers that frame VYNE today
- Market cap
- $19.05M
- P/E (TTM)
- -0.9
- EV / FCF
- 0.2
- Gross margin
- 100%
- EV / Sales
- -12.3
- ROIC
- -257.3%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $7.85
- 52wk High
- $44.54
Growth
Revenue and earnings trend for VYNE
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about VYNE
Is Vyne Therapeutics a good buy?
No. Vyne Therapeutics has strong momentum, but poor quality undercuts the setup. Growth looks poor. That could put pressure on the long-term business case.
What is the market capitalization of VYNE?
Vyne Therapeutics's market capitalization is $19.05M.
What is the P/E ratio for VYNE stock?
Vyne Therapeutics's current P/E ratio is -0.9.
What is the 52-week high for VYNE stock?
The 52-week high for Vyne Therapeutics is $44.54. The current close of $28.56 is 35.9% below that high.
What is the 52-week low for VYNE stock?
The 52-week low for Vyne Therapeutics is $7.85. The current close of $28.56 is 264% above that low.
Does VYNE stock pay dividends?
Vyne Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for VYNE?
Vyne Therapeutics's Debt / Equity ratio is 0.